| Cisplatin | advanced breast cancer (metastatic), in all type of patients | vs CAF | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Costanza, 1999 | carboplatin followed by CAF | immediate chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil (CAF) | women with measurable metastatic breast cancer, previously untreated with chemotherapy for their metastatic disease |
| |
| Cisplatin | | vs CFP | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Creagan ET, 1984 | four cycles of cyclophosphamide, Adriamycin (Adria Laboratories, Inc, Columbus, Ohio), cisplatin (CAP) followed by maintenance with cyclophosphamide, 5-fluorouracil, prednisone (CFP) | | |
| |
| Cisplatin | | vs CMF | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Cocconi, 1999 | The same single agents (C, M, F, cisplatin, etoposide, and doxorubicin) were administered in both experimental arms, but following a different policy. | cyclophosphamide, methotrexate, and 5-fluorouracil | | | Cocconi, 1991 | cisplatin (P) and etoposide (E) | standard cyclophosphamide, methotrexate, and fluorouracil (CMF) | | | Cocconi G, 1996 | | | |
| |
| Cisplatin | | vs CMFVP | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Kolaric, 1985 | | | |
| |
| Cisplatin | | vs ECycloF | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Eisen, 1998 | | | |
| |
| Cisplatin | | vs EPI | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Nielsen, 2000 | | | |
| |
| Cisplatin | | vs FAC | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Kolaric, 1989 | | | |
| |
| Cisplatin | | vs lonidamine + epirubicin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Berruti A, 2002 | cisplatin + epirubicin | lonidamine + epirubicin | | | Berruti B, 2002 | | | |
| |
| Cisplatin | | vs paclitaxel | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Icli, 2002 | | | |
| |
| Cisplatin | | vs PE | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Trial | Studied treatment | Control | Patients |
|---|
| Fountzilas, 2002 | | | |
| |
